The aim of this study has been to identify a new potential approach for treating chemo-resistant NB and to this end we have industrialized an imidazo-pyrazole enriched drug delivery system by a nanotechnological approach, and we have tested its activity on ETO-sensitive (HTLA-230) and ETO-resistant (HTLA-ER) NB cells. This evidence concerns the gene RUNX1T1 and neuroblastoma.